Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23965900.
- Also identified by DOI 10.1158/1078-0432.CCR-13-1923 and PMC identifier 3817012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.
Medical subject headings
- Antibodies, Blocking
- Antibodies, Monoclonal
- CD8-Positive T-Lymphocytes
- CTLA-4 Antigen
- Neoplasms